Show simple item record

dc.contributor.authorSvendsen, Bjørneng
dc.contributor.authorMyhr, Kjell-Morteneng
dc.contributor.authorNyland, Harald Ingeeng
dc.contributor.authorAarseth, Jan Haraldeng
dc.date.accessioned2011-03-11T10:03:17Z
dc.date.available2011-03-11T10:03:17Z
dc.date.issued2010-11-16eng
dc.identifier.citationThe European Journal of Health Economics 1-11en_US
dc.identifier.issn1618-7598eng
dc.identifier.urihttp://hdl.handle.net/1956/4568
dc.description.abstractHealth economic aspects have been increasingly important during introduction of new treatments for multiple sclerosis. As a partial response for Norway, a costof- illness study was carried out to estimate the yearly cost of the illness to society and relate costs and patients’ quality of life to illness severity. Estimated cost to society was Euro 439 million in 2002 exclusive of the cost of reduced quality of life. The cost per patient was close to Euro 65,000. Account taken of methodological differences, the results compare to results for Sweden, Norway’s closest neighboring country. The illness reduced patients’ quality of life with 0.26. More patients were early retired because of their MS in Norway than in any of nine other European countries comprised by a recent European study, illustrating a liberal practice in Norway. The Norwegian cost of unpaid assistance was almost identical to the Swedish cost that was the lowest found across the countries in the European study. When related to illness severity, the cost per patient increased, and the patients’ experienced quality of life decreased with increasing EDSS levels in line with what has been found for other countries. Cost-of-MS studies have been carried out for a number of countries. Together they contribute to our understanding of the economic consequences of multiple sclerosis and, if their results are related to illness severity, also provide valuable information for further economic analyses of treatment and medication. Our study adds to this.en_US
dc.language.isoengeng
dc.publisherSpringereng
dc.rightsAttribution-NonCommercial CC BY-NCeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc/2.5/eng
dc.subjectMultiple sclerosiseng
dc.subjectCost-of-illnesseng
dc.subjectQuality of lifeeng
dc.subjectRelapseeng
dc.subjectEDSSeng
dc.subjectNorwayeng
dc.titleThe cost of multiple sclerosis in Norwayeng
dc.typePeer reviewedeng
dc.typeJournal articleeng
dc.subject.nsiVDP::Medical disciplines: 700eng
dc.rights.holderCopyright The Author(s) 2010. This article is published with open access at Springerlink.com
dc.rights.holderThe Author(s) 2010eng
dc.type.versionpublishedVersioneng
bora.peerreviewedPeer reviewedeng
bora.cristinID922561eng
bibo.doihttp://dx.doi.org/10.1007/s10198-010-0286-7eng
dc.identifier.cristinID922561eng
dc.identifier.doihttp://dx.doi.org/10.1007/s10198-010-0286-7


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial CC BY-NC
Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC